CN114249816B - 一种重组蛋白质药物的分子设计 - Google Patents

一种重组蛋白质药物的分子设计 Download PDF

Info

Publication number
CN114249816B
CN114249816B CN202111201002.3A CN202111201002A CN114249816B CN 114249816 B CN114249816 B CN 114249816B CN 202111201002 A CN202111201002 A CN 202111201002A CN 114249816 B CN114249816 B CN 114249816B
Authority
CN
China
Prior art keywords
ser
leu
ala
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111201002.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114249816A (zh
Inventor
罗永章
刘鹏
鲁薪安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Priority to CN202111201002.3A priority Critical patent/CN114249816B/zh
Publication of CN114249816A publication Critical patent/CN114249816A/zh
Application granted granted Critical
Publication of CN114249816B publication Critical patent/CN114249816B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202111201002.3A 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计 Active CN114249816B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111201002.3A CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201510079486 2015-02-13
CN2015100794867 2015-02-13
CN2015107361842 2015-11-02
CN201510736184 2015-11-02
PCT/CN2016/073773 WO2016127948A1 (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计
CN202111201002.3A CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计
CN201680010044.XA CN107428809B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680010044.XA Division CN107428809B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Publications (2)

Publication Number Publication Date
CN114249816A CN114249816A (zh) 2022-03-29
CN114249816B true CN114249816B (zh) 2024-09-06

Family

ID=56614147

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111201002.3A Active CN114249816B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计
CN201680010044.XA Active CN107428809B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680010044.XA Active CN107428809B (zh) 2015-02-13 2016-02-14 一种重组蛋白质药物的分子设计

Country Status (7)

Country Link
US (2) US10869910B2 (cg-RX-API-DMAC7.html)
EP (1) EP3269731B1 (cg-RX-API-DMAC7.html)
JP (1) JP6896636B2 (cg-RX-API-DMAC7.html)
CN (2) CN114249816B (cg-RX-API-DMAC7.html)
AU (2) AU2016218635B2 (cg-RX-API-DMAC7.html)
DK (1) DK3269731T5 (cg-RX-API-DMAC7.html)
WO (1) WO2016127948A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148277B (zh) * 2014-11-03 2022-03-22 清华大学 一种抑制脂肪细胞分化和胰岛素耐受的药物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Also Published As

Publication number Publication date
AU2020256316B2 (en) 2021-10-07
DK3269731T3 (da) 2023-10-30
DK3269731T5 (da) 2024-10-14
WO2016127948A1 (zh) 2016-08-18
US10869910B2 (en) 2020-12-22
CN107428809B (zh) 2021-10-01
US20180200337A1 (en) 2018-07-19
EP3269731A4 (en) 2018-08-15
CN114249816A (zh) 2022-03-29
JP6896636B2 (ja) 2021-06-30
CN107428809A (zh) 2017-12-01
EP3269731A1 (en) 2018-01-17
AU2016218635A1 (en) 2017-10-05
AU2020256316A1 (en) 2020-11-12
CA3014538A1 (en) 2016-08-18
JP2018507854A (ja) 2018-03-22
US20210085754A1 (en) 2021-03-25
AU2016218635B2 (en) 2020-07-23
EP3269731B1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
JPH01501283A (ja) 新規な型のコロニー刺激因子―1
CN106279423B (zh) Slit2D2-HSA融合蛋白及其在抗肿瘤中的应用
CN116836233B (zh) 抗炎活性多肽及其应用
CN111388680B (zh) 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物
CN111378049B (zh) 抗肿瘤靶向融合蛋白、其偶联物及用途
CN114796525B (zh) 细胞周期调控蛋白抑制剂在肿瘤治疗中的应用
AU2020256316B2 (en) Molecular design of recombinant protein drug
CN101497886A (zh) 一种真菌硫氧还蛋白的多肽、编码序列及制备方法和应用
CA3014538C (en) Molecular design of recombinant protein drug
CN103865899B (zh) 具有vegfr2/kdr受体特异性的融合毒素及其编码基因与应用
CN100398557C (zh) 血管生成抑制多肽及其制备方法和应用
US6893844B1 (en) DNA encoding a new human hepatoma derived growth factor and producing method thereof
CN112574286A (zh) 多肽及其应用
JPS6034915A (ja) ポリペプチド
HK1240943B (en) Molecular design of recombinant protein drug
HK1240943A1 (en) Molecular design of recombinant protein drug
CN111094357B (zh) 一类新的Bcl10聚合抑制剂及其应用
CN1952129B (zh) Angptl4缺失突变体及其应用
JPH06306100A (ja) Vipアナログ調製用融合蛋白、vipアナログの製法並びにそのための遺伝子組換えプラスミド及び形質転換微生物
WO2004091650A1 (fr) Utilisation de la troponine i cardiaque pour preparer des medicaments antitumoraux
CN100480264C (zh) 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列
CN101062948B (zh) 单体速效胰岛素及其制法和用途
CN101144081A (zh) 核苷酸分子trail及其在制备治疗肿瘤药物中的应用
CN101817878B (zh) 单体速效胰岛素及其制法和用途
CN101824082B (zh) N端缺失型p43蛋白及其在肿瘤治疗药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant